# 1. Financial Performance ## A. Key Figures * Revenue: ₹673 Cr Q3 (+4.8% YoY, +14.4% QoQ) · ₹1,863 Cr 9M (+7.2% YoY) * Gross Margin: 58.9% Q3 (+330 bps YoY) · 57.3% 9M * EBITDA Margin: 36.4% Q3 (+510 bps YoY, record high) · 33.3% 9M (+400 bps YoY) * **PAT:** ₹150 Cr Q3 (3% margin) · ₹402 Cr 9M (6% margin) * **Operating Cash Flow (pre-CAPEX):** ₹439 Cr (9M) ## B. Revenue Growth * **Record Quarterly Revenue:** Top-line reached new highs with broad-based strength across CDMO, API generics, and GPL segments. * **Diversified Global Demand:** Growth supported by expanding footprint in Europe, Japan, LATAM, ROW, and India, reflecting resilient international demand. ## C. Profit Margins * **Historic Margin Expansion:** EBITDA margin hit all-time high on favorable product mix, new launches, and **operational efficiencies** including improved yields and lower input costs. * **Sustainable Margin Profile:** CDMO business delivers superior, stable margins versus generics, with further upside from execution rigor and capacity optimization. * **Strategic Margin Discipline:** Company prioritizes high-quality, high-margin revenue over volume-driven models to preserve cash flow and working capital integrity. ## D. Cash Flow * **Strong Cash Generation:** Robust operating cash flow underscores earnings quality and self-funding capacity ahead of reinvestment. ## E. Balance Sheet * **Asset Turnover Transition:** Ratio currently at 3x but expected to decline short-term due to **CAPEX cycle**, with long-term stabilization targeted without margin dilution. * **Cash Position & M&A Outlook:** Balance sheet remains cash-rich with growing liquidity; inorganic opportunities will be selectively pursued only if strategically aligned. --- # 2. Product & Therapy Performance ## A. Key Figures * CDMO Revenue Growth: 100% QoQ (85.3% YoY) * **Chronic Therapies Revenue Contribution:** **66%** of total Q3 FY'26 revenue * **CVS & CNS Revenue Contribution:** **51%** of total Q3 FY'26 revenue ## B. CDMO Segment * **Strong Recovery & Momentum:** CDMO segment rebounded sharply in Q3 with robust QoQ growth, driven by new and ongoing project traction, signaling successful second-half turnaround. * **Project Pipeline Progress:** Early supply shipments underway; **1–2 new projects expected by Q1 next fiscal**, expanding on current base of five active projects. * **Regulatory Timing Risk:** Near-term ramp-up constrained by **lag in regulatory approvals** in regulated markets despite commercial progress. ## C. API Generics * **Growth Divergence:** Late double-digit growth anticipated in generics API business, fueled by **upcoming patent expiries across multiple geographies**. * **Portfolio Mix Shift:** Mature products show stable but limited growth (2%-3%), while newer launches tied to **patent expiries within two years** expected to drive outsized gains via alternate sourcing opportunities. * **Strategic Prioritization:** Management emphasizes **cost-benefit discipline** in pursuing new opportunities, prioritizing high-margin generics performance. ## D. Chronic Therapies * **Dominant Revenue Driver:** Chronic therapies remain the core growth engine, with **CVS and CNS alone representing over half of quarterly revenue**. ## E. High Potency Portfolio * **Long-Term Growth Vector:** High potency portfolio expected to become **meaningful contributor starting late FY'28**, indicating multi-year investment horizon. --- # 3. Capacity & Manufacturing ## A. Key Figures * **Capacity Expansion:** **2,100 KL** total (from 1,400 KL) (**400 KL** for backward integration) * **Capacity Utilization:** **>90%** current · **85–90%** expected in FY'27 * **Solapur Initial Capacity:** **450–500 KL** (revised from 600 KL) * **Revenue from Regulated Markets:** **>80%** * Phase-3 Clinical Batch Volumes (Ireland): 8–10 million units ## B. Solapur Expansion * **Slight Delay, No Impact:** Solapur launch delayed by three months to **July**, but business remains unaffected due to strong regulated-market coverage from on-track Dahej and Ankleshwar expansions. * **De-risked Scale-up:** Initial Solapur capacity reduced to **450–500 KL** to prevent under-absorption, reflecting disciplined demand-aligned scaling. * **Strategic Role Evolution:** Facility to initially serve **ROW markets**, enabling reallocation of existing capacity to regulated segments; long-term shift to reg markets expected but not timed. * **Margin Capture Opportunity:** Solapur’s ramp-up will allow **in-sourcing of high-margin outsourced products**, reducing vendor dependency and boosting profitability. * **Enhanced Flexibility & Surge Capacity:** Integration of Solapur will expand surge capacity, supporting new CDMO and innovator projects, including cross-utilization across inspected sites. ## C. Brownfield Projects * **Near-Term Capacity Secured:** Brownfield expansions at Dahej and Ankleshwar—coming online in **Q2 next year**—resolve current constraints and ensure sufficient capacity for **regulated markets for two+ years**. * **Supply Chain Resilience:** Active **relocation of sourcing back to India** reduces exposure to Chinese suppliers and strengthens operational control. ## D. Utilization & Volume Trends * **High Utilization, Strategic Buffer:** Operating at **>90% utilization**, expansions ensure ability to capture volume growth despite **market price erosion**. * **CDMO Efficiency Model:** Maintains **~85% utilization** to preserve **surge capacity**, balancing absorption risk with responsiveness; minimal EBITDA impact expected. * **Backward Integration Focus:** **400 KL** of new capacity dedicated to BI for high-revenue molecules (**₹40–50 Cr** each), securing supply and protecting margins. ## E. Innovator & Pre-Commercial Activity * **Robust Pre-Commercial Pipeline:** Ireland site actively producing **N-1 stage batches** for tax compliance, with Phase-3 volumes indicating **advanced clinical-stage momentum**. * **Innovator Project Readiness:** Confirmed ability to **cross-utilize existing capacities** for Tarang and other innovator programs, backed by inspected facilities and continuity planning. --- # 4. R&D & Technology ## A. Key Figures * R&D Expenditure: ₹23 Cr Q3 FY'26 (3.4% of sales) · ₹66 Cr 9M FY'26 (3.5% of sales) * **Pipeline Scale:** **595** DMF and CEP filings as of Dec 31, 2025 * **HPAPI Pipeline:** **27** products in development, including **9 validated**, **7 advanced**, **11 lab-stage** * **TAM:** $70 Bn total addressable market for pipeline ## B. Flow Chemistry * **Strategic Focus:** Flow chemistry selectively deployed for **high-volume APIs** with long reaction times and high reagent use, driving material and energy efficiency. * **Application Limits:** Not universally applicable due to **in-situ conversions**, **multi-step batch reactions**, and **low-volume HPAPIs** (post-2028), where batch remains optimal. * **Technical Parity:** Company maintains **industry-leading capability** in complex processes, including flow chemistry and particle engineering, despite implementation constraints. ## C. Particle Engineering * **API Plus Growth:** Particle engineering integrated into R&D to enable **enhanced formulations** and capture new commercial opportunities. ## D. New Product Pipeline * **Next-Gen Process Shield:** Advanced processes in pipeline to offset price erosion, protecting **margin integrity** on at-risk products. * **Capacity Expansion:** New R&D facility launched to accelerate development of **increasingly complex molecules** and strengthen innovation velocity. --- # 5. Client & Market Mix ## A. Key Figures * **Non-GPL Revenue:** **70–75%** of total revenue (low to mid-teens growth) * **New CDMO Project Size:** **₹4–6 Cr** per project (pipeline range) * **Target Market Share:** **20–25%** in select post-patent markets (e.g., Brazil) ## B. Non-GPL Revenue * **Margin Expansion from New Launches:** Higher-margin contributions from recent product rollouts in Europe, China, LATAM, and Russia, with further runway tied to patent expiries in Europe and North America. * **CDMO Momentum Building:** Projects 4 and 5 on track for volume ramp in H2, supporting sustainable margin uplift alongside a robust platform of regulatory approvals and process development. * **Integrated Growth Model:** CDMO leverages shared R&D and manufacturing infrastructure with API business, enabling efficient scaling and resource optimization. * **Strategic Validation:** Management and board affirm commitment to CDMO path, citing strong YoY execution and a distinctive niche, despite questions on accelerating growth given competitive scientific talent. ## C. Geography Mix * **Resilient Global Demand:** Underlying drivers—aging populations, chronic disease, and healthcare spending—are supporting recovery in generics, APIs, and CDMO services globally. * **Global Footprint Paying Off:** Early geographic diversification (5–6 years ago) is now contributing meaningfully to growth, with market-specific share targets achievable through front-end partnerships. ## D. Customer Filings * **Enhanced CDMO Credibility:** Post-separation from Glenmark, innovator clients view the business more favorably, reducing perceived conflicts and boosting new business interest. * **Launch Timing Dictated by Patents:** While filings for newer molecules are complete, commercial launches remain pending patent expirations, creating a staged market entry profile. --- # 6. Risks & Regulatory ## A. Key Figures * **Pricing Erosion Guidance:** **4%–5%** margin impact expected, deemed manageable * **China Procurement Exposure:** **<10%** of raw materials solely sourced from China, with no single vendor dependence ## B. Pricing Erosion * **Stable Pricing Environment:** Pricing remains resilient across the portfolio, supported by locked-in contracts in regulated markets and balanced input cost dynamics. * **Currency & Cost Management:** Near-term cost stability maintained despite **Renminbi strength** and **Rupee weakness**, underpinned by long-duration supply contracts. * **Portfolio-Level Cost Balance:** Raw material volatility is offset across products, enabling stable overall input costs despite spot fluctuations. ## C. Project Scalability * **Scalability Challenge:** CDMO model faces constraints due to low per-project revenue run rates and long gestation periods, limiting rapid scale-up. * **Market Opportunity Gap:** Large-scale CDMO opportunities remain scarce as big pharma retains control of high-value patented assets. * **High-Risk Strategic Options:** Proposed scalability initiatives under internal review but flagged as **high-risk** by management. ## D. Geopolitical Exposure * **Diversified Risk Mitigation:** Geographic diversification and a multi-vendor supply base reduce exposure to geopolitical shocks, proven during prior disruptions. * **China Sourcing Resilience:** Continued sourcing from China for cost efficiency, backed by **Indian alternate suppliers** to ensure continuity if required. ## E. Regulatory Scrutiny * **Elevated Regulatory Environment:** Industry-wide tightening of oversight and supply chain de-risking efforts are shaping operational planning and compliance focus. --- # 7. Guidance & Outlook ## A. Key Figures * **Revenue Growth Outlook:** **High single-digit** growth expected for FY'26 * **Volume Growth Requirement:** **15%–17%** volume growth needed to offset 5% price erosion * **EBITDA Margin Guidance:** **30%–32%** (up from 28%–30%) * **CDMO Revenue Target:** Goal to double by 2025 (2022 roadshow) ## B. Revenue Forecast * **Growth Drivers:** High single-digit revenue growth underpinned by **profitable expansion in non-GPL segments** and ongoing CDMO project ramp-up. * **Price-Volume Dynamic:** Revenue mix reflects **5% price erosion** over 9MFY'26, with volume growth accounting for the balance. * **CAPEX Resilience:** Recent capacity adjustments and project delays not expected to impact near-term growth trajectory. ## C. Margin Target * **Margin Expansion Confirmed:** Full-year EBITDA margin guidance raised to **30%–32%**, driven by operational efficiencies and new product contributions. ## D. Growth Timeline * **Long-Term Growth Inflection:** Management signals **double-digit growth from FY'28–'29**, contingent on full Solapur facility ramp-up post-backward integration. * **Sustainable Over Aggressive:** Strategy emphasizes **adaptive, sustainable growth** despite strong financials, prioritizing cash generation and stability. * **Organic Roadmap Clear:** Growth plans include structured portfolio development, molecule selection, and capacity build-out ahead of key launches. ## E. CDMO Expansion * **Solapur Regulatory Path:** Dual focus this year on validating shortage products to trigger FDA inspection and serving ROW markets; **regulated product launches expected by late FY'28**. * **Pipeline Momentum:** **Two additional CDMO projects** in advanced stages, with confirmation expected by **Q1 FY'27**, contributing from **FY'28** onward. * **Inorganic Strategy:** M&A under active review with emphasis on **prudent capital deployment**; action reserved for **strategically aligned opportunities**. * **Investor Pressure Mounting:** Concerns persist over **slower-than-expected CDMO execution**, with calls for more aggressive growth following delayed 2025 doubling target.